Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 TrialStefan Dietzsch, Martin Mynarek, Jutta Welzel et al.|Advances in Radiation Oncology|2020Cited by 22
Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studiesDenise Obrecht, Stefan Rutkowski, Martin Mynarek et al.|Journal of Neuro-Oncology|2022Cited by 5
MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?Denise Obrecht, Stefan Rutkowski, Martin Mynarek et al.|Neuro-Oncology|2020Cited by 0
MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIALStefan Dietzsch, Martin Mynarek, Felix Placzek et al.|Neuro-Oncology|2020Cited by 0